Kevin Michael Coveney - 23 Dec 2025 Form 4 Insider Report for Enveric Biosciences, Inc. (ENVB)

Signature
/s/ Kevin Michael Coveney
Issuer symbol
ENVB
Transactions as of
23 Dec 2025
Net transactions value
$0
Form type
4
Filing time
30 Dec 2025, 16:37:07 UTC
Previous filing
12 May 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Coveney Kevin Michael Chief Financial Officer 245 FIRST STREET, RIVERVIEW II, 18TH FLOOR, CAMBRIDGE /s/ Kevin Michael Coveney 30 Dec 2025 0001967056

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ENVB Common Stock Award $0 +40,198 +557% $0.000000 47,413 23 Dec 2025 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the restricted stock units (the "RSUs") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the "Company") 2020 Long-Term Incentive Plan, as amended. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. One-fourth of the RSUs will vest upon the one-year anniversary of the date of issuance. An additional one-thirty-sixth of the RSUs will vest each month following the first vesting date. Any remaining RSUs will vest on the fourth anniversary of the date of issuance. Vesting is conditioned upon continued employment by the Company.
F2 On October 28, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 12 shares of issued and outstanding common stock were reclassified as one share of common stock (the "Reverse Stock Split"). The amount of securities reported in this Form 4 has been adjusted to reflect the Reverse Stock Split.